DarioHealth (NASDAQ:DRIO) vs. Echo Therapeutics (OTCMKTS:ECTE) Critical Survey

Echo Therapeutics (OTCMKTS:ECTE) and DarioHealth (NASDAQ:DRIO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

33.4% of DarioHealth shares are held by institutional investors. 7.0% of Echo Therapeutics shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Echo Therapeutics and DarioHealth”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A
DarioHealth	$21.19 million	2.70	-$41.71 million	($8.88)	-0.88

Echo Therapeutics has higher earnings, but lower revenue than DarioHealth.

Profitability

This table compares Echo Therapeutics and DarioHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Echo Therapeutics	N/A	N/A	N/A
DarioHealth	-192.23%	-60.52%	-37.08%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Echo Therapeutics and DarioHealth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Echo Therapeutics	0	0	0	0	0.00
DarioHealth	1	1	1	0	2.00

DarioHealth has a consensus target price of $10.50, indicating a potential upside of 34.79%. Given DarioHealth’s stronger consensus rating and higher possible upside, analysts plainly believe DarioHealth is more favorable than Echo Therapeutics.

Summary

DarioHealth beats Echo Therapeutics on 5 of the 9 factors compared between the two stocks.

About Echo Therapeutics

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.